| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 3.06▲ | 3.03▲ | 3.03▲ | 2.92▲ | 2.98▲ |
| MA10 | 3.03▲ | 3.01▲ | 3.00▲ | 2.86▲ | 4.14▼ |
| MA20 | 3.03▲ | 3.00▲ | 2.99▲ | 2.97▲ | 4.46▼ |
| MA50 | 3.00▲ | 2.94▲ | 2.82▲ | 4.14▼ | 10.60▼ |
| MA100 | 2.98▲ | 2.83▲ | 2.88▲ | 4.41▼ | 13.57▼ |
| MA200 | 2.91▲ | 2.91▲ | 3.10▲ | 9.07▼ | 20.83▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.008▲ | 0.004▲ | 0.003▲ | 0.099▲ | 0.183▲ |
| RSI | 69.168▲ | 67.194▲ | 64.912▲ | 45.861▼ | 36.826▼ |
| STOCH | 80.712▲ | 77.699 | 75.265 | 62.672 | 16.379▼ |
| WILL %R | -7.692▲ | -5.714▲ | -3.774▲ | -5.714▲ | -82.843▼ |
| CCI | 160.762▲ | 228.034▲ | 199.508▲ | 111.971▲ | -85.484 |
|
Thursday, August 14, 2025 02:24 AM
Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody ...
|
|
Wednesday, August 13, 2025 02:28 PM
Key Points Jasper Therapeutics (NASDAQ:JSPR) reported a GAAP loss per share of $1.74 for Q2 2025. Research and development expenses (GAAP) nearly doubled to $21.2 million in Q2 2025 from $11.3 million ...
|
|
Wednesday, August 13, 2025 01:19 PM
Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 15/08/25 | 3.05 | 3.14 | 2.945 | 3.11 | 322,987 |
| 14/08/25 | 2.91 | 3.04 | 2.81 | 3.03 | 296,900 |
| 13/08/25 | 2.85 | 3.03 | 2.8108 | 2.97 | 219,496 |
| 12/08/25 | 2.67 | 2.87 | 2.60 | 2.85 | 222,100 |
| 11/08/25 | 2.54 | 2.74 | 2.521 | 2.63 | 285,000 |
| 08/08/25 | 2.75 | 2.84 | 2.45 | 2.45 | 588,764 |
| 07/08/25 | 2.90 | 2.969 | 2.70 | 2.73 | 379,379 |
| 06/08/25 | 2.972 | 2.98 | 2.86 | 2.90 | 158,964 |
| 05/08/25 | 3.00 | 3.04 | 2.9101 | 2.98 | 186,423 |
| 04/08/25 | 2.88 | 2.98 | 2.811 | 2.97 | 190,163 |
|
|
||||
|
|
||||
|
|